Rifabutin-based triple therapy wipes out H. pylori in infected patients
The novel rifabutin-based triple therapy (RHB-105) delivers promising outcomes as first-line empirical treatment for Helicobacter pylori eradication, according to the results of a phase III, double blind trial. This therapy addresses the challenge of rising antibiotic resistance in the current environment.
